📊 IKT Key Takeaways
Is Inhibikase Therapeutics, Inc. (IKT) a Good Investment?
Inhibikase is a pre-commercial biotech company with minimal revenue ($3.7M) and severe operating losses ($52M), burning $27.8M in annual cash flow. While the balance sheet is exceptionally strong with $178.8M cash and negligible debt, current burn rate depletes cash in 6-7 years without revenue growth or additional capital. The fundamental operational performance indicates an extremely high-risk, development-stage company dependent entirely on uncertain clinical outcomes.
IKT is deeply unprofitable with minimal revenue and extreme negative margins, but it holds a very strong, cash‑heavy balance sheet with negligible debt and exceptional liquidity, providing a multi‑year runway. The fundamental outlook hinges on curbing cash burn and demonstrating durable revenue traction before profitability is plausible.
Why Buy Inhibikase Therapeutics, Inc. Stock? IKT Key Strengths
- Exceptional liquidity with $178.8M cash and 21.7x current ratio provides extended runway for clinical development
- Minimal debt ($381.8K) and 0.00x debt-to-equity ratio eliminates financial distress risk in near term
- Strong stockholders' equity of $172.9M provides substantial capital buffer for R&D investments
- Cash-rich balance sheet (~$179M) versus low liabilities (~$8.3M)
- Minimal leverage and interest burden
- Very high liquidity (current ratio ~21.7x) and low capex needs
IKT Stock Risks: Inhibikase Therapeutics, Inc. Investment Risks
- Severe cash burn of $27.8M annually against minimal $3.7M revenue creates unsustainable long-term trajectory
- Negative operating margin of -1399% and net margin of -1299% indicate no clear path to profitability at current scale
- Pre-commercial biotech stage with undefined clinical pipeline success probabilities and likely future dilutive financing needs
- Persistent large operating losses and highly negative margins
- Sustained cash burn raising dilution/financing risk if spending increases
- Limited revenue base with uncertain scalability and visibility
Key Metrics to Watch
- Quarterly operating cash flow burn rate and cash runway remaining
- Revenue growth trajectory and clinical trial advancement milestones
- Dilution from future equity financing and pipeline clinical trial results
- Operating cash flow (burn/runway)
- Revenue growth and operating margin improvement
Inhibikase Therapeutics, Inc. (IKT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 21.70x current ratio provides a solid financial cushion.
IKT Profit Margin, ROE & Profitability Analysis
IKT vs Healthcare Sector: How Inhibikase Therapeutics, Inc. Compares
How Inhibikase Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inhibikase Therapeutics, Inc. Stock Overvalued? IKT Valuation Analysis 2026
Based on fundamental analysis, Inhibikase Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inhibikase Therapeutics, Inc. Balance Sheet: IKT Debt, Cash & Liquidity
IKT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inhibikase Therapeutics, Inc.'s revenue has declined by 92% over the 5-year period, indicating business contraction. The most recent EPS of $-1.16 indicates the company is currently unprofitable.
IKT Revenue Growth, EPS Growth & YoY Performance
IKT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$4.6M | $-0.13 |
| Q2 2025 | N/A | -$4.6M | $-0.11 |
| Q1 2025 | N/A | -$4.6M | $-0.15 |
| Q3 2024 | N/A | -$4.5M | $-0.65 |
| Q2 2024 | N/A | -$4.5M | $-0.66 |
| Q1 2024 | N/A | -$4.5M | $-0.73 |
| Q3 2023 | $7.3K | -$4.5M | $-0.86 |
| Q2 2023 | $6.6K | -$4.5M | $-1.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inhibikase Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
IKT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inhibikase Therapeutics, Inc. (CIK: 0001750149)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IKT
What is the AI rating for IKT?
Inhibikase Therapeutics, Inc. (IKT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IKT's key strengths?
Claude: Exceptional liquidity with $178.8M cash and 21.7x current ratio provides extended runway for clinical development. Minimal debt ($381.8K) and 0.00x debt-to-equity ratio eliminates financial distress risk in near term. ChatGPT: Cash-rich balance sheet (~$179M) versus low liabilities (~$8.3M). Minimal leverage and interest burden.
What are the risks of investing in IKT?
Claude: Severe cash burn of $27.8M annually against minimal $3.7M revenue creates unsustainable long-term trajectory. Negative operating margin of -1399% and net margin of -1299% indicate no clear path to profitability at current scale. ChatGPT: Persistent large operating losses and highly negative margins. Sustained cash burn raising dilution/financing risk if spending increases.
What is IKT's revenue and growth?
Inhibikase Therapeutics, Inc. reported revenue of $3.7M.
Does IKT pay dividends?
Inhibikase Therapeutics, Inc. does not currently pay dividends.
Where can I find IKT SEC filings?
Official SEC filings for Inhibikase Therapeutics, Inc. (CIK: 0001750149) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IKT's EPS?
Inhibikase Therapeutics, Inc. has a diluted EPS of $-0.49.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IKT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inhibikase Therapeutics, Inc. has a SELL rating with 69% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IKT stock overvalued or undervalued?
Valuation metrics for IKT: ROE of -27.9% (sector avg: 15%), net margin of -1,299.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IKT stock in 2026?
Our dual AI analysis gives Inhibikase Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IKT's free cash flow?
Inhibikase Therapeutics, Inc.'s operating cash flow is $-27.8M, with capital expenditures of $13.4K. FCF margin is -748.3%.
How does IKT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,299.0% (avg: 12%), ROE -27.9% (avg: 15%), current ratio 21.70 (avg: 2).